A pair of late-stage biotechs submitted IPO plans last week as industry insiders gear up for what could be a handful of post-Labor Day public debut pitches. To repeat: That’s a handful of IPOs, not an overflowing basket of filings like the days of 2021 that saw at least 100 biotech IPOs. But any sign … Continue reading Handful of biotechs expected to IPO this fall, but many are stuck in ‘holding pattern’ until 2024